Table 8 Clinical trials-pomalidomide
From: Thalidomide and its analogues in the treatment of Multiple Myeloma
Author | Regimen(s) | Type of disease/ clinical trial | No. of pts | Best responses (>PR) | CR, nCR, VGPR | PFS/TTP/OS (months) | References |
|---|---|---|---|---|---|---|---|
Lacy M et al | Pd | Relapsed & refractory disease/Phase I | 60 | 63% | CR:5% VGPR:28% PR:30% | PFS:11.6 | J Clin Oncol 2009 |
Schey et al | P | Relapsed & refractory disease/Phase I | 24 | 54% | CR:17%VGPR:13% PR:25% | Not reported | J Clin Oncol 2004 |
Streetly et al | P | Relapsed & refractory disease/Phase I | 20 | 50% | CR:10% VGPR:30% PR:10% | PFS:10.5 OS:33 | Br J Haematol 2008 |
Lacy M et al | Pd | Lenalinomide & bortezomib refractory disease/Phase I | 34 | 50% | VGPR:3% PR:29% MR:18% | Not reported | ASCO 2010 |
Richardson P et al | Pd | Lenalinomide refractory disease/Phase I | 32 | 52% | PR:28% | Not reported | ASH 2009 |